VIVEbiotech is a Contract Development and Manufacturing Organization -CDMO- developing and manufacturing lentiviral vectors under GMP standards with wide and robust experience in manufacturing vectors for rare/ultrarare diseases and for immune-cell therapy projects i.e. CAR-Ts, TCRs...
VIVEbiotech is currently working on more than 35 projects according to both the FDA´s and the EMA´s regulations, and is manufacturing vectors for companies based in the US, Europe, Asia and Australia.
VIVEbiotech has an R&D department as well as two process optimization departments for both upstream -USP- production and downstream -DSP- purification. The activities of these departments consist of improving the cost-effectiveness, scalability, regulatory or quality compliance of the production process, and the intrinsic biological characteristics of the vectors themselves.
VIVEbiotech very recently expanded facilities and has now seven cleanrooms fully and specifically set up for lentiviral-vector manufacturing. This has allowed significantly increasing our production capacity.
In these facilities VIVEbiotech will be capable of manufacturing from early-stage to clinical- and commercial-scale batches.